EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Beneficial Effects of Ursodeoxycholic Acid on Metabolic Parameters and Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Randomized Double‐Blind, Placebo‐Controlled Clinical Study

Biljana Lakić iD, Ranko Škrbić iD, Snežana Uletilović, Nebojša Mandić-Kovačević, Milkica Grabež iD, Mirna Popović Šarić, Miloš P Stojiljković iD, Ivan Soldatović, Zorica Janjetović iD, Anastasija Stokanović, Nataša Stojaković, Momir Mikov

Journal of Diabetes Research · 2024

DOI: 10.1155/2024/4187796 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes Research, 2024. Verfasst von Biljana Lakić und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Ursodeoxycholic Acid. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oxidative stress and inflammation are closely related pathophysiological processes, both occurring in type 2 diabetes mellitus (T2DM). In addition to the standard treatment of T2DM, a potential strategy has been focused on the use of bile acids (BAs) as an additional treatment. Ursodeoxycholic acid (UDCA), as the first BA used in humans, improves glucose and lipid metabolism and attenuates oxidative stress. The aim of this study was to evaluate the potential metabolic, anti‐inflammatory, and antioxidative effects of UDCA in patients with T2DM.

Methods

This prospective, double‐blind, placebo‐controlled clinical study included 60 patients with T2DM, randomly allocated to receive UDCA or placebo. Subjects were treated with 500 mg tablets of UDCA or placebo administered three times per day (total dose of 1500 mg/day) for eight weeks. Two study visits, at the beginning (F0) and at the end (F1) of the study, included the interview, anthropometric and clinical measurements, and biochemical analyses.

Results

UDCA treatment showed a significant reduction in body mass index ( p = 0.024) and in diastolic blood pressure ( p = 0.033), compared to placebo. In addition, there was a statistically significant difference in waist circumference in the UDCA group before and after treatment ( p < 0.05). Although no statistical significance was observed at the two‐month follow‐up assessment, an average decrease in glucose levels in the UDCA group was observed. After two months of the intervention period, a significant decrease in the activity of liver enzymes was noticed. Furthermore, a significant reduction in prooxidative parameters (TBARS, NO 2 - , H 2 O 2 ) and significant elevation in antioxidative parameters such as SOD and GSH were found ( p < 0.001).

Conclusions

The eight‐week UDCA administration showed beneficial effects on metabolic and oxidative stress parameters in patients with T2DM. Thus, UDCA could attenuate the progression and complications of diabetes and should be considered as an adjuvant to other diabetes treatment modalities. This trial is registered with NCT05416580 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Ursodeoxycholic AcidHumansGlucoseHydrogen PeroxideOxidative StressProspective Studies

Substanzen

GlucoseHydrogen PeroxideUrsodeoxycholic Acid

Autor:innen und Institutionen

  • Department of Family Medicine, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
  • Primary Health Care Centre, Banja Luka, Bosnia and Herzegovina.
  • Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
  • Centre for Biomedical Research, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
  • Department of Medical Biochemistry and Chemistry, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
  • Department of Pharmacy, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.

ORCID-Profile: Biljana Lakić, Ranko Škrbić, Milkica Grabež, Miloš P Stojiljković, Zorica Janjetović

Zitieren

APA

Lakić, B., Škrbić, R., Uletilović, S., Mandić-Kovačević, N., Grabež, M., Šarić, M. P., Stojiljković, M. P., Soldatović, I., Janjetović, Z., Stokanović, A., Stojaković, N., & Mikov, M. (2024). Beneficial Effects of Ursodeoxycholic Acid on Metabolic Parameters and Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Randomized Double‐Blind, Placebo‐Controlled Clinical Study. Journal of Diabetes Research. https://doi.org/10.1155/2024/4187796

Vancouver

Lakić B, Škrbić R, Uletilović S, Mandić-Kovačević N, Grabež M, Šarić MP, et al. Beneficial Effects of Ursodeoxycholic Acid on Metabolic Parameters and Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Randomized Double‐Blind, Placebo‐Controlled Clinical Study. Journal of Diabetes Research. 2024. doi:10.1155/2024/4187796

BibTeX
@article{Laki2024,
  author = {Lakić, Biljana and Škrbić, Ranko and Uletilović, Snežana and Mandić-Kovačević, Nebojša and Grabež, Milkica and Šarić, Mirna Popović and Stojiljković, Miloš P and Soldatović, Ivan and Janjetović, Zorica and Stokanović, Anastasija and Stojaković, Nataša and Mikov, Momir},
  title = {Beneficial Effects of Ursodeoxycholic Acid on Metabolic Parameters and Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Randomized Double‐Blind, Placebo‐Controlled Clinical Study},
  journal = {Journal of Diabetes Research},
  year = {2024},
  doi = {10.1155/2024/4187796}
}
Kostenlos starten →